Free tools Windows power users keep installed
One-click scans. No signup required.
Tirzepatide produced greater average weight loss than semaglutide in the 72-week SURMOUNT-5 head-to-head trial. The comparison is not a guarantee for any individual: participants did not have diabetes, the trial was open-label, and both medicines were increased to each participant’s maximum tolerated dose. Both are prescription injections used alongside reduced-calorie eating and increased physical activity, and both can cause gastrointestinal side effects. The appropriate choice depends on the labeled indication, medical history, other medicines, response, tolerability, access, and a prescriber’s judgment.
At a glance: how the two medicines compare
| Question | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| Head-to-head average weight reduction at 72 weeks | 13.7% of baseline weight | 20.2% of baseline weight |
| Weekly starting dose for U.S. weight-management labeling | 0.25 mg once weekly for 4 weeks | 2.5 mg once weekly for 4 weeks; this is an initiation dose, not a maintenance dose |
| Adult maintenance options for weight management | 1.7 mg or recommended 2.4 mg once weekly | 5 mg, 10 mg, or 15 mg once weekly |
| Distinct U.S. labeled use highlighted in current labeling | Chronic weight management and cardiovascular-risk reduction for certain adults with established cardiovascular disease | Chronic weight management and treatment of moderate-to-severe obstructive sleep apnea in adults with obesity |
| Common tolerability issue | Gastrointestinal symptoms, including nausea, diarrhea, vomiting, constipation, and abdominal symptoms | Gastrointestinal symptoms, including nausea, diarrhea, vomiting, constipation, and abdominal symptoms |
The percentages in the first row are trial averages, not expected results for every patient. The products are not interchangeable by milligram, and neither should be started, stopped, combined, or adjusted without the prescribing clinician.
As an Amazon Associate I earn from qualifying purchases.
What the SURMOUNT-5 head-to-head trial actually tested
Study design and population
SURMOUNT-5 was a phase 3b, randomized, open-label trial conducted in the United States and Puerto Rico. It randomized 751 adults in a 1:1 ratio and followed them for 72 weeks. Participants had obesity, or overweight with a weight-related condition, and did not have diabetes. Each group followed a dose-escalation plan and continued to the maximum tolerated dose allowed by the study protocol.
Quick wins for a faster PC:
Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Clear out junk files and repair common Windows errorsFree Scan →The trial compared tirzepatide at 10 mg or 15 mg with semaglutide at 1.7 mg or 2.4 mg. Most participants reached the higher dose in their assigned range. The reported treatment-regimen estimand describes average weight change under the assigned treatment regimen; it is not an individual forecast and does not mean every participant reached the same dose or lost the same amount.
#1 Best Overall
What the result means
Tirzepatide’s average reduction was 6.5 percentage points greater than semaglutide’s in this trial. That is a difference between group means, not proof that tirzepatide will work better for a particular person. Some people respond strongly to either medicine, some have a smaller response, and some must remain at a lower dose or discontinue because of adverse effects.
Important limits on the comparison
- The participants did not have diabetes, so the result should not be presented as a direct prediction for people with type 2 diabetes.
- The study was open-label: participants and investigators knew which medicine was being used.
- The trial was designed primarily to compare weight reduction, not to establish that one medicine is safer or easier to tolerate.
- Because treatment was titrated to maximum tolerated doses, the comparison is between full regimens rather than between identical milligram doses.
- The release reporting the result came from the manufacturer and reported simultaneous publication in the New England Journal of Medicine in 2025. A peer-reviewed paper is the preferred source for detailed methods and safety analyses.
How these results relate to earlier weight-loss trials
Earlier placebo-controlled trials provide context, but they were separate studies with different participants, follow-up periods, designs, and comparators. Their percentages cannot be treated as a head-to-head ranking.
| Trial and medicine | Regimen reported | Average change reported | Follow-up |
|---|---|---|---|
| STEP 1, semaglutide | 2.4 mg | −14.9% | Week 68 |
| SURMOUNT-1, tirzepatide | 5 mg | −15.0% | Week 72 |
| SURMOUNT-1, tirzepatide | 10 mg | −19.5% | Week 72 |
| SURMOUNT-1, tirzepatide | 15 mg | −20.9% | Week 72 |
These figures are selected estimates summarized by The Obesity Society from the named trials. Different placebo groups, eligibility rules, titration schedules, durations, and analysis methods can change the apparent size of an effect. The SURMOUNT-5 result is the more relevant evidence when the question is a direct comparison between the two medicines, but it still applies most directly to people resembling that trial’s population.
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Scan for outdated or missing drivers - takes under a minute3Clear out junk files and repair common Windows errorsStarting, escalating, and maintaining the weekly doses
Both U.S. weight-management products begin below their eventual maintenance dose. Gradual escalation is intended to improve gastrointestinal tolerability. The schedule below is the labeled framework, not a personal prescription.
Rank #2
- Made in USA - Proudly produced in Ohio by a Veteran-owned business
- Comprehensive Tracking: This log book provides dedicated sections to track daily and weekly health metrics, including weight, diet, exercise, and medication side effects.
- Detailed Personal Records: Keep a thorough record of your health conditions, allergies, and GLP-1 medication specifics, such as the starting date, dosage, and injection schedule.
- Goal-Oriented Features: The log book helps you stay motivated by allowing you to record personal motivations, exercise goals, and track your progress with starting and ending weight and waist circumference measurements.
- Reorder SKU: LOG-104-M3CW-PP(GLP-1)
| Label element | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| Initial dose | 0.25 mg once weekly for 4 weeks | 2.5 mg once weekly for 4 weeks |
| How escalation works | Increase at 4-week intervals; delay escalation if the current dose is not tolerated | Increase by 2.5 mg after at least 4 weeks at the current dose |
| Adult maintenance options for weight management | 1.7 mg or recommended 2.4 mg once weekly | 5 mg, 10 mg, or 15 mg once weekly |
| Administration | Subcutaneous injection on the same day each week, with or without meals | Subcutaneous injection once weekly; follow the instructions for the specific presentation |
Why the starting doses are not comparable by number
A 2.5 mg tirzepatide starting dose is not equivalent to a 2.5 mg semaglutide dose. The medicines are different molecules with different labeled dose ranges. Comparing the numbers directly can lead to an unsafe substitution.
What to do if a dose is difficult to tolerate
The labels allow escalation to be delayed when a dose is not tolerated. A prescriber may keep a patient at the current dose, postpone the next increase, or reassess the treatment plan. Do not compensate for a delayed dose by taking extra medicine, and do not use another GLP-1 receptor agonist at the same time unless a clinician has specifically directed a medically appropriate transition.
Switching or combining
The labels advise against coadministration with other GLP-1 receptor agonists. Switching requires a plan that accounts for the last dose, timing, current symptoms, other medicines, and the new product’s escalation schedule. A comparison article cannot safely supply a universal switch interval.
How weekly administration fits into real life
Keep the weekly routine consistent
Choose a weekly day that can be maintained and follow the product-specific instructions for the injection device. Semaglutide’s weight-management labeling permits administration with or without meals. Tirzepatide’s instructions depend on the specific presentation, so the package insert and pharmacist’s demonstration take priority over generalized internet instructions.
Track the dose and symptoms
- Record the date, dose, and injection presentation after each use.
- Note nausea, vomiting, diarrhea, constipation, abdominal pain, appetite changes, and any symptom that interferes with eating or drinking.
- Tell the prescriber about insulin, insulin secretagogues, medicines affecting fluid balance, and every nonprescription product.
- Before planned anesthesia or deep sedation, tell the anesthesia and procedural teams that you use the medicine.
Dispose of used devices safely
Put used needles or injection devices into a sharps-disposal container that matches the device instructions, then follow local rules for closing and discarding the container. A household trash or recycling stream may not be permitted in your area. The correct container and disposal route depend on the product presentation and local regulations.
Side effects: where the labels overlap and where they differ
Common effects
Gastrointestinal symptoms are the main overlap. Nausea, diarrhea, vomiting, constipation, and abdominal symptoms are listed for both medicines. They are often most noticeable during dose escalation, but a symptom that is persistent, severe, or associated with dehydration needs medical advice rather than an automatic dose increase.
| Effect or issue | What the available labeling says | Practical implication |
|---|---|---|
| Nausea, diarrhea, vomiting, constipation | Listed among common adverse effects for both products | Escalation may need to be delayed; report inability to keep fluids down |
| Abdominal pain and indigestion | Abdominal symptoms and dyspepsia are reported; tirzepatide labeling also lists gastroesophageal reflux disease and eructation | Persistent or severe pain should be evaluated instead of being assumed to be routine |
| Injection-site reactions | Listed in tirzepatide labeling | Discuss a recurring or worsening reaction with the prescriber |
| Fatigue, hair loss, hypersensitivity reactions | Listed in tirzepatide labeling | New or concerning symptoms warrant a medication review |
Exact frequencies vary by dose, study, population, and product presentation. The head-to-head report described adverse events as primarily gastrointestinal and generally mild to moderate, but it was not powered to prove a tolerability advantage for either medicine. A lower discontinuation rate in one study should not be converted into a general safety claim.
Serious warnings shared by both labels
- Thyroid C-cell tumors: Both labels carry a boxed warning based on rodent findings. Whether the finding applies to humans is unknown. A personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) is listed among the contraindications.
- Pancreatitis: Severe or persistent abdominal pain, especially with vomiting or pain radiating to the back, requires prompt medical assessment.
- Gallbladder disease: Gallstones and related gallbladder problems are addressed in both labels. New right-upper-abdominal pain, fever, jaundice, or repeated vomiting should not be ignored.
- Kidney injury from volume depletion: Prolonged vomiting or diarrhea can reduce fluid volume and impair kidney function. Contact the care team if fluids cannot be maintained.
- Hypersensitivity: Swelling of the face or throat, trouble breathing, widespread hives, or a rapidly worsening reaction is an emergency.
- Hypoglycemia in relevant combinations: Risk can increase when these medicines are used with insulin or insulin-secretagogue medicines. Dose changes for those medicines require the treating clinician.
Warnings that are not identical
Wegovy labeling includes a warning about diabetic retinopathy complications in patients with type 2 diabetes. Zepbound labeling addresses the possibility of aspiration during anesthesia or deep sedation. These differences do not mean one product has no risk in the other category; they indicate that the labels call out different evidence and situations. Tell every clinician involved in diabetes care, eye care, surgery, or sedation which medicine and dose you use.
Approved U.S. uses are not interchangeable
| Use | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| Chronic weight management | Yes, for labeled adults and eligible pediatric patients under the product’s criteria | Yes, for adults meeting the labeled criteria |
| Cardiovascular-risk reduction | Indicated for certain adults with established cardiovascular disease and obesity or overweight | Not the weight-management indication highlighted in the supplied labeling comparison |
| Obstructive sleep apnea | Not the indication highlighted in the supplied labeling comparison | Indicated for moderate-to-severe obstructive sleep apnea in adults with obesity |
Eligibility depends on the complete label, including body-mass-index thresholds, associated conditions, age, and contraindications. An indication does not guarantee insurance coverage, and using a medicine for a different purpose may involve a separate clinical and regulatory assessment.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.How a clinician chooses between them
1. Match the medicine to the condition being treated
Established cardiovascular disease may make Wegovy’s cardiovascular-risk-reduction indication relevant for an eligible adult. Moderate-to-severe obstructive sleep apnea with obesity may make Zepbound’s OSA indication relevant. If the goal is weight management alone, both products have a labeled role, so the remaining factors become more important.
2. Review contraindications and risk history
The prescriber should ask about MTC or MEN 2 in the family, prior pancreatitis, gallbladder disease, kidney problems, severe gastrointestinal symptoms, diabetic retinopathy, allergies, diabetes medicines, and upcoming anesthesia or deep sedation. The same body weight or diagnosis can lead to a different choice when the medical history differs.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
3. Set expectations around response
The head-to-head averages favor tirzepatide in the studied population, but averages conceal a wide range of individual outcomes. The clinically useful question is not only which group mean was higher, but whether a person can reach and maintain a tolerated dose, achieve meaningful improvement, and continue safely.
Best Value
- Made in USA - Proudly produced in Ohio by a Veteran-owned business
- Comprehensive Tracking: This log book provides dedicated sections to track daily and weekly health metrics, including weight, diet, exercise, and medication side effects.
- Detailed Personal Records: Keep a thorough record of your health conditions, allergies, and GLP-1 medication specifics, such as the starting date, dosage, and injection schedule.
- Goal-Oriented Features: The log book helps you stay motivated by allowing you to record personal motivations, exercise goals, and track your progress with starting and ending weight and waist circumference measurements.
- Reorder SKU: LOG-104-69CW-PP(GLP-1)
4. Consider the escalation experience
Both medicines require several weeks of stepwise increases. Someone who has troublesome gastrointestinal symptoms at one step may need a longer interval or a lower maintenance dose. A person who cannot tolerate escalation may not resemble the maximum-tolerated-dose participants in the trial, so the trial average becomes less informative for that individual.
5. Check the complete medication and access picture
Review every prescription and nonprescription medicine, especially insulin or insulin secretagogues. Then verify the exact product, presentation, pharmacy supply, prior-authorization rules, copay, and refill process. There is no single reliable current price or insurance answer for all patients: costs and coverage vary by country, region, insurer, plan, and date.
Questions to ask before the first prescription
- Which labeled indication am I being treated for?
- What is my starting dose, and on what date would the first increase occur?
- What symptoms mean I should delay an increase or call the clinic?
- How will diabetes medicines be adjusted if low blood sugar becomes a concern?
- Do my thyroid, pancreas, gallbladder, kidney, eye, or allergy history change the choice?
- What should I tell the anesthesia team before a procedure?
- Which injection presentation am I receiving, and how should it be stored and discarded?
- What will the medicine cost under my specific insurance or self-pay arrangement?
Making sense of the headline result
Tirzepatide is the stronger average performer in the available direct comparison, but that finding should be read with its boundaries: a 72-week, open-label study in adults without diabetes, using maximum tolerated doses and not designed to establish a safety winner. Semaglutide remains a distinct option with its own cardiovascular-risk-reduction indication for certain adults. Both require gradual titration, monitoring for gastrointestinal and other adverse effects, and clinician supervision.
Recommended Free Tools
The safest decision is therefore not a universal ranking. It is a product-specific plan that fits the person’s indication, contraindications, other medicines, ability to tolerate escalation, treatment response, and coverage.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
